According to Dr. Reddy’s contract development and manufacturing organization (CDMO) arm, the 70,000 square-foot facility will develop and manufacture modalities such as therapeutic proteins, antibodies, and viral vectors.
The site, situated in Genome Valley, comprises already operational R&D laboratories, while the manufacturing facility is slated for completion later this year. At the time of announcement in July 2023, with an investment of ₹330 crore ($40 million), the site was said to create up to 270 jobs in the region, the firm confirmed.
“The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational and the addition of this capacity and capabilities shows our firm commitment to the continued expansion of our biologics business, building on 25 years of proven experience. The facility will enable us to service our global customers efficiently and support the development of innovative medicine,” said Aurigene CEO, Akhil Ravi.
The Genome Valley facility is equipped with chemistry, manufacturing, and controls (CMC) services aided by a team ensuring a smooth transfer of large-scale commercial manufacturing, said the firm.
“There are very few global CDMOs that can truly support customers ‘end-to-end' from discovery services to large-scale commercial manufacture of both drug substance and drug product,” said Roger Lias, global commercial head of biologics, Aurigene.
“Our new facility further strengthens Aurigene’s capabilities and builds on our technical excellence, demonstrated global compliance and state-of-the-art facilities as companies from start-up biotechs to global multinationals continue to strengthen their supply chains and seek economically viable support for both their development portfolios and marketed products.”
You May Also Like
